Clinical Trials Sponsored by Roche Chugai

Total 3256 results

Hoffmann-La Roche

Completed

A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab

Metastatic Colorectal Cancer

Belgium
Hoffmann-La Roche

Completed

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps (POLYP 2)

Nasal Polyps | Chronic Rhinosinusitis

Spain, United States, Belgium, France, Poland, Hungary, Finland, Mexico, Russian Federation, Ukraine
Hoffmann-La Roche

Completed

A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer (HerSCin)

Breast Neoplasms

Germany
Hoffmann-La Roche

Completed

Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

Rheumatoid Arthritis

France
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (ATALK)

Carcinoma, Non-Small-Cell Lung

France
Hoffmann-La Roche

Completed

Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

Multiple Myeloma

United States, Australia, United Kingdom
Hoffmann-La Roche

Completed

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

Giant Cell Arteritis

United States, United Kingdom, Sweden, Belgium, Netherlands, Germany, Spain, Norway, Poland, France, Italy, Canada, Denmark, Portugal
Hoffmann-La Roche

Completed

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Lymphoma

United States, France, Germany, Italy, United Kingdom
Hoffmann-La Roche

Completed

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

Coronary Heart Disease

Germany, United States
Hoffmann-La Roche

Completed

A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors

Solid Tumors

United States, Denmark, Spain, Switzerland, Netherlands, Canada
Hoffmann-La Roche

Completed

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

Malignant Melanoma

South Africa
Hoffmann-La Roche

Terminated

A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

Metastatic Breast Cancer

Saudi Arabia
Hoffmann-La Roche

Completed

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Coronary Heart Disease

Belgium, Germany, Israel, Poland, Spain, United Kingdom, China, Korea, Republic of, United States, France, Switzerland, Canada, Ireland, New Zealand, South Africa, Hungary, Netherlands, Australia, Puerto Rico, Sweden, Austria, Arg... and more
Hoffmann-La Roche

Completed

A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients

Coronary Heart Disease

Switzerland, France, Germany, Netherlands, Austria, Italy, United Kingdom
Hoffmann-La Roche

Completed

An Observational Study to Register the Incidence of Breast Cancer and Current Clinical Care Patterns in Kenya

Breast Cancer

Kenya
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)

Non-Squamous Non-Small Cell Lung Cancer

United States, Italy, Canada, Austria, Finland, France, Greece, Korea, Republic of, Panama, Portugal, Spain, Turkey, United Kingdom, Taiwan, Brazil, Germany, Poland, Chile, Guatemala, Russian Federation, Switzerland, Thailand, Ukraine, Serb... and more
Hoffmann-La Roche

Completed

A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers

Healthy Volunteer

New Zealand
Hoffmann-La Roche

Completed

A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis

Bronchitis

Peru
Hoffmann-La Roche

Completed

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

Colorectal Cancer

Canada, United States, Italy, Korea, Republic of, United Kingdom, Belgium, Russian Federation, Hong Kong, Spain, Australia, Poland
Hoffmann-La Roche

Completed

Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA) (SIMPACT)

Rheumatoid Arthritis

Hungary
Hoffmann-La Roche

Completed

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

Juvenile Idiopathic Arthritis

Belgium, Canada, United States, Argentina, Poland, Spain, Germany, Hungary
Hoffmann-La Roche

Completed

A Study to Investigate the Effect of Itraconazole on the PK of Multiple Doses of Balovaptan in Healthy Volunteers

Healthy Volunteers

Netherlands
Hoffmann-La Roche

Completed

Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants

Rheumatoid Arthritis

Serbia, Germany, France, Russian Federation, Italy, Tunisia
Hoffmann-La Roche

Completed

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Non-small Cell Lung Cancer

Belgium, Italy, Portugal, Spain, Germany, Turkey, France, Hong Kong, Korea, Republic of, Poland, Russian Federation, Hungary, Norway, Bulgaria, Slovakia
Hoffmann-La Roche

Completed

Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia

Breast Cancer

Saudi Arabia
Hoffmann-La Roche

Completed

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Chronic Renal Anemia

Belgium, Brazil, United Kingdom, Serbia, Spain, Germany, Korea, Republic of, Turkey, Lithuania, Italy, Czechia, Argentina, Australia, Croatia, France, Greece, Israel, Malaysia, Mexico, Panama, Philippines, Poland, Russian Federation, ... and more
Hoffmann-La Roche

Completed

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

Colorectal Cancer

Spain, United States
Hoffmann-La Roche

Completed

A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)

Muscular Atrophy, Spinal

Belgium, United Kingdom, Germany, France, Italy, Netherlands, Poland
Hoffmann-La Roche

Completed

OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Participants With Chronic Kidney Disease Stages 3 and 4 Not on Dialysis (OPTIMA)

Anemia

Greece
Hoffmann-La Roche

Completed

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab (MabCute)

Non-Hodgkin's Lymphoma

Italy, Russian Federation, United Kingdom, Brazil, Ecuador, Germany, Slovenia, Spain, Norway, Switzerland, France, Hungary, Romania, Austria, Albania, Bulgaria, Slovakia, Sweden, Turkey, Argentina, Colombia, Greece, Egypt, Lithuania
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Bladder Cancer

United States, France, Belgium, Korea, Republic of, United Kingdom, Czechia, Austria, Canada, Denmark, Greece, Italy, Netherlands, Portugal, Slovenia, Spain, Sweden, Turkey, Poland, Hungary, Switzerland, Japan, Taiwan, Australia, Norway, Germa... and more
Hoffmann-La Roche

Completed

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States, Australia
Hoffmann-La Roche

Completed

An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

Solid Tumor

Spain, Russian Federation, France, Japan, South Africa, Latvia, Serbia, Italy
Hoffmann-La Roche

Completed

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma (BRIM8)

Melanoma

United States, Israel, Italy, Spain, Belgium, United Kingdom, Austria, Czechia, France, Netherlands, New Zealand, Russian Federation, Australia, Canada, Croatia, Portugal, Germany, Ukraine, Switzerland, Argentina, Brazil, Ireland, N... and more
Hoffmann-La Roche

Completed

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Breast Neoplasms

Canada, United States, France, Korea, Republic of, Spain, Belgium, Germany, Russian Federation, Taiwan, Ukraine
Hoffmann-La Roche

Terminated

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors (TITAN)

Advanced or Metastatic Solid Tumors

United States
Hoffmann-La Roche

Terminated

Study of Intravenous RXDX-107 in Patients With Solid Tumors

Solid Tumor

United States
Hoffmann-La Roche

Terminated

A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status

Lymphocytic Leukemia, Chronic

Russian Federation
Hoffmann-La Roche

Terminated

A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

Non-Small Cell Lung Cancer

United States, Italy, Hungary, Spain, United Kingdom, Russian Federation, Korea, Republic of, Greece, Romania, Poland, France, Germany, Czechia, Serbia
Hoffmann-La Roche

Completed

Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Korea, Republic of, United Kingdom, Italy, Russian Federation, Argentina, Belgium, Brazil, Panama, Germany, Japan, Ukraine, Chile, South Africa, Bulgaria, Romania
Hoffmann-La Roche

Completed

A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer (ASCENT)

Colorectal Neoplasms

Australia
Hoffmann-La Roche

Completed

A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Spain
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.

Hepatitis D, Chronic

Turkey
Hoffmann-La Roche

Completed

Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment (CONIFER)

Rheumatoid Arthritis

Germany
Hoffmann-La Roche

Completed

A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent (ACT-MOVE)

Rheumatoid Arthritis

United Kingdom
Hoffmann-La Roche

Completed

Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer

Breast Neoplasms

China
Hoffmann-La Roche

Completed

Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China

Non-Small Cell Lung Cancer, Lung Cancer, Cancer

China
Hoffmann-La Roche

Completed

A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy (TOSCA)

Rheumatoid Arthritis

France
Hoffmann-La Roche

Completed

A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Non-Squamous Non-Small Cell Lung Cancer

Portugal
Hoffmann-La Roche

Terminated

A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice

Rheumatoid Arthritis

Saudi Arabia

3

Subscribe